TCWM
CYCN icon

Total Clarity Wealth Management’s Cyclerion Therapeutics CYCN Stock Holding History

Total Clarity Wealth Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75
Closed -$5K – 998
2021
Q3 		$5K Buy
+75
New +$4.91K ﹤0.01% 809

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Total Clarity Wealth Management's CYCN Position: Q4 2021 in Review

Total Clarity Wealth Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 75 shares — an estimated $5K sold.

Total Clarity Wealth Management first reported a position in CYCN in Q3 2021 and held it in 1 quarter. The position peaked at $5K in Q3 2021. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Total Clarity Wealth Management reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Total Clarity Wealth Management sold 75 Cyclerion Therapeutics shares in Q4 2021, an estimated $5K.
  • Total Clarity Wealth Management first reported a position in Cyclerion Therapeutics in Q3 2021 and held it in 1 quarter.
  • Total Clarity Wealth Management's Cyclerion Therapeutics position peaked at $5K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Total Clarity Wealth Management's 13F filing for Q4 2021, filed 3 Feb 2022.